Benjamin Graham fit · Defensive deep-value investing
Is Apellis Pharmaceuticals, Inc. (APLS) a Benjamin Graham Stock?
Meets 2/7 Graham criteria - classic deep-value candidate.
79/100
DNot a fit
2/7 criteria passed
+8 sector-quality lift. Top-quintile within its sector on 4 of 5 quality metrics. Raw pillar score 71 → lifted to 79 before grade derivation.
Capped from B to D. Net income negative for most of the last 5 years - Graham required earnings stability What are deal-breaker caps?
Benjamin Graham's Criteria, Applied to APLS
P/E ≤ 15
key38.8x
P/B ≤ 1.5
key12.5x
Current ratio ≥ 2
3.6x
Debt / Equity ≤ 1
1.1x
How APLS Scores on Other Strategies
Live Financial Snapshot
Market cap
$5.25B
P/E (TTM)
38.8x
ROIC (TTM)
18.11%
Gross margin
90.12%
Other Benjamin Graham fit reports
Frequently Asked Questions
What is APLS's Benjamin Graham fit score?
APLS scores 79/100 on our Benjamin Graham fit engine - grade D. Meets 2/7 Graham criteria - classic deep-value candidate.
Does Benjamin Graham actually own APLS?
Our score is computed from financial fundamentals against Benjamin Graham's published criteria. We don't claim that Benjamin Graham personally owns or recommends APLS.
How often is this score updated?
APLS's Benjamin Graham fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Benjamin Graham personally owns or recommends APLS.